Entity

Time filter

Source Type

OKLAHOMA CITY, OK, United States

Ataga K.I.,University of North Carolina at Chapel Hill | Stocker J.,Selexys Pharmaceuticals Corporation
British Journal of Haematology | Year: 2015

Although sickle cell disease (SCD) is highly prevalent worldwide, it is a rare disease in the United States and Europe. Over the past decade, there has been an increased understanding of the pathophysiology of SCD. While multiple drugs have been tested, only one drug, hydroxycarbamide, is approved by the relevant regulatory agencies specifically for this disease. Due to the combination of an improved understanding of disease pathophysiology, governmental support and the success of several recently approved drugs for other orphan diseases, there is an increased interest in the development of targeted drugs for SCD. Novel drugs that are currently being evaluated include haemoglobin F inducers, anti-sickling agents, anti-oxidants, anti-adhesive agents, anti-inflammatory agents, anticoagulants and anti-platelet agents. In addition to the evaluation of acute pain crisis as a study endpoint, clinical trials employing other SCD-related complications, exercise capacity, as well as patient reported outcomes are warranted and necessary in order to advance the development of these novel therapeutic agents. Finally, despite the availability of multiple biomarkers, many of these are of limited clinical value in SCD and require further assessment in prospective studies to validate their prognostic importance before they are acceptable as surrogate endpoints. © 2015 John Wiley & Sons Ltd. Source


Miwa H.E.,Yeshiva University | Song Y.,Yeshiva University | Alvarez R.,The University of Oklahoma Health Sciences Center | Alvarez R.,Selexys Pharmaceuticals Corporation | And 3 more authors.
Glycoconjugate Journal | Year: 2012

The bisecting GlcNAc is transferred to the core mannose residue of complex or hybrid N-glycans on glycoproteins by the β1,4-N- acetylglucosaminyltransferase III (GlcNAcT-III) or MGAT3. The addition of the bisecting GlcNAc confers unique lectin recognition properties to Nglycans. Thus, LEC10 gain-of-function Chinese hamster ovary (CHO) cells selected for the acquisition of ricin resistance, carry N-glycans with a bisecting GlcNAc, which enhances the binding of the erythroagglutinin E-PHA, but reduces the binding of ricin and galectins-1, -3 and -8. The altered interaction with galactose-binding lectins suggests that the bisecting GlcNAc affects N-glycan conformation. LEC10 mutants expressing polyoma middle T antigen (PyMT) exhibit reduced growth factor signaling. Furthermore, PyMT-induced mammary tumors lacking MGAT3, progress more rapidly than tumors with the bisecting GlcNAc on N-glycans of cell surface glycoproteins. In recent years, evidence for a new paradigm of cell growth control has emerged involving regulation of cell surface residency of growth factor and cytokine receptors via interactions and cross-linking of their branched N-glycans with a lattice of galectin(s). Specific cross-linking of glycoprotein receptors in the lattice regulates their endocytosis, leading to effects on growth factor-induced signaling. This review will describe evidence that the bisecting GlcNAc of N-glycans regulates cellular signaling and tumor progression, apparently through modulating N-glycan/galectin interactions. © Springer Science+Business Media, LLC 2012. Source


Patent
Selexys Pharmaceuticals Corporation | Date: 2013-02-01

The invention features antibodies, e.g., chimeric and humanized antibodies, that recognize (i.e., bind) P-selectin. The P-selectin antibodies prevent P-selectin from binding to its cognate receptor. The P-selectin antibodies can be used to treat inflammatory and thrombotic conditions, e.g., sickle cell disease, pain crisis associated with sickle cell disease, deep vein thrombosis, asthma, rheumatoid arthritis, psoriasis, and ischemia reperfusion injury in a patient in need thereof.


Selexys Pharmaceuticals Corporation | Entity website

Welcome to Selexys Pharmaceuticals At Selexys, we are committed to advancing the understanding of inflammation and developing novel products to treat inflammatory diseases. Our business is focused on helping patients who suffer these afflictions enjoy better and longer lives ...


Selexys Pharmaceuticals Corporation | Entity website

Selexys Pharmaceuticals Completes $23M Equity Financing and Signs Agreement With Global Pharmaceutical Company Sept. 19, 2012 OKLAHOMA CITY - Selexys Pharmaceuticals, Corp ...

Discover hidden collaborations